Your Article Summary
See Latest ArticlesResponses After Completion of Therapy Increase Pixantrone CR/CRu Rate to 24% and ORR to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial
Cell Therapeutics, 06/23/09
Cell Therapeutics, Inc. announced that an overview of CTI's pixantrone clinical studies in aggressive and indolent NHL including follow-up data and subgroup analyses of high risk patients from the phase III EXTEND PIX 301 clinical trial of pixantrone is being presented at the Pan Pacific Lymphoma conference by Dr. Richard Van der Jagt of the Ottawa General Hospital.
Today in Drug Trials...keeping you current
Receive free subspecialty "5-minute updates" via email
Second Pivotal Phase III Study of Gileads Darusentan for Resistant Hypertension Misses Primary Endpoints
Gilead, 12/15/09
Genentech and Biogen Idec Announce Positive Results From First Phase III Trial of Ocrelizumab in Rheumatoid Arthritis
Genentech, 12/15/09
Primary endpoint reached in Active Biotechs TASQ Phase II clinical trial in prostate cancer patients
Active Biotech, 12/15/09